| Name | Title | Contact Details |
|---|
American Global is a prominent privately held insurance and surety brokerage firm based in Miami, Florida. With over 100 locations worldwide, the company specializes in construction risk management. Their mission focuses on understanding client needs and creating tailored solutions, fostering long-term partnerships to enhance the brokerage experience. The firm offers a wide range of services, including managing complex surety programs, providing consultative insurance solutions, and designing captive finance options. They also create Controlled Insurance Programs (CIPs) and Subcontractor Default Insurance (SDI) programs to help clients minimize costs and manage risks effectively. American Global serves a diverse clientele in the construction industry, including general contractors and construction management firms. The company promotes a culture of innovation and collaboration, encouraging employees to contribute to the future of construction brokerage. American Global has been recognized as one of the "Best Places to Work" by Business Insurance for two consecutive years, reflecting their commitment to employee satisfaction and development.
Perimeter Solutions is a global specialty chemicals company based in Clayton, Missouri, established in 1963. The company focuses on two main areas: fire safety solutions and lubricant additives. It is a market leader in both sectors, particularly known for its wildfire retardants, firefighting foams, and industrial fire suppressants. Perimeter Solutions offers a range of products, including water-enhancing gels and preventative fire retardants, catering to government agencies, municipalities, and industrial clients worldwide. In addition to fire safety, Perimeter Solutions specializes in niche engine oil additives, holding a significant market share in this area. These additives improve lubricant performance for both automotive and industrial applications. The company is publicly traded under the ticker PRM and is co-founded by Nick Howley, who also chairs the company. With a strong emphasis on innovation and a robust manufacturing and distribution network, Perimeter Solutions positions itself as a premier provider of chemical solutions in its industries.
Founded in 1904, the Fédération Internationale de Football Association (FIFA) is the umbrella organisation of its members, currently 211 national football associations. Its main objectives, enshrined in its statutes, are to develop football around the world, to stage international competitions and to protect the integrity of football (against match manipulation, doping etc.). FIFA is composed of a number of political bodies (such as the FIFA Congress and the FIFA Council) and the administration. The highest political position is the FIFA President, elected every four years by FIFAs member associations. The FIFA administration, with more than 800 people from over 60 nations, is based in Zurich. It is run by the Secretary General (CEO). FIFA stages FIFA World Cups™ in various forms such as youth, mens and womens, futsal, beach soccer or club competitions. The mens FIFA World Cup™ is not only the most popular single sporting event in the world but also the financial backbone for FIFA and its efforts to develop football worldwide. The financial success of the FIFA World Cup™ allows FIFA to run a wide range of football development programmes and to provide funds, infrastructure and know-how to its member associations through the FIFA Forward Development Programme. For more information visit our website.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.